Maven Securities LTD Abb Vie Inc. Transaction History

Maven Securities LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1.13 Million - $1.3 Million	8,448 New	8,448 $11.3 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $326,914 - $405,608	-2,477 Reduced 47.38%	2,751 $446,000
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $497,293 - $629,219	-4,629 Reduced 46.96%	5,228 $708,000
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $80,970 - $91,913	761 Added 8.37%	9,857 $1.06 Million
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $648,304 - $722,248	6,162 Added 210.02%	9,096 $1.03 Million
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $31,917 - $35,137	312 Added 11.9%	2,934 $318,000
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $211,044 - $284,932	2,622 New	2,622 $281,000

3,785

1.28B

13M

9.82M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $355B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.